Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis

Blood Cancer J. 2018 May 24;8(5):46. doi: 10.1038/s41408-018-0086-3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Biomarkers, Tumor
  • Biopsy
  • Flow Cytometry*
  • Humans
  • Immunoglobulin Light-chain Amyloidosis / diagnosis*
  • Immunoglobulin Light-chain Amyloidosis / therapy
  • Immunophenotyping
  • Neoplasm, Residual / diagnosis*

Substances

  • Biomarkers
  • Biomarkers, Tumor